CardioDx is a cardiovascular genomic diagnostics company located in Redwood City, California. The company is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia, and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. CardioDx performs the Corus CAD test in its onsite clinical laboratory which has been certified by the Centers for Medicare and Medicaid Services (CMS) according to the Clinical Laboratory Improvements Amendments (CLIA) and is accredited by the College of American Pathologists (CAP). The CardioDx laboratory is licensed to perform tests for all 50 states.
Missing: CardioDx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CardioDx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing CardioDx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
CardioDx is included in 5 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
CardioDx has filed 6 patents.
Heart diseases, Vascular diseases, Cardiac arrhythmia, Cardiology, Numerical climate and weather models
Heart diseases, Vascular diseases, Cardiac arrhythmia, Cardiology, Numerical climate and weather models
Latest CardioDx News
May 22, 2020
Former iRhythm, CardioDx Executive Assumes Reimbursement Role at Clarify Medical New recruit has more than 25 years of experience in the medical device industry. Business Wire05.22.20 Clarify Medical has appointed Linda Kotcher as vice president of Market Access and Reimbursement, effective immediately. Kotcher brings to Clarify Medical over 25 years of healthcare experience in the medical device field with a focus on managed care contracting, provider relations, reimbursement, healthcare policy, and health economics. Most recently, Kotcher served as senior director, U.S. Market Access and Reimbursement, for Heartflow, and previously worked in market access leadership roles at iRhythm, CardioDx, Pathworks Diagnostics, and Dexcom. “Linda’s extensive experience and successful track record of establishing market access for novel medical technologies will undoubtedly bolster our commercialization of the Clarify System,” said George Mahaffey, president and CEO of Clarify Medical. “Because the Clarify System is the only connected and monitored home NB-UVB phototherapy system on the market, we can actually demonstrate improved treatment adherence rates, thereby improving patient outcomes and potentially delaying or avoiding escalation to more expensive therapies. We are pleased to welcome Linda to the team to broaden market access for this new therapeutic option.” The Clarify System, which has been cleared by the U.S. Food and Drug Administration, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of targeted narrowband UVB (NB-UVB) light therapy; the System helps to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis and The Vitiligo Working Group Recommendations for NarrowBand Ultraviolet B Light Phototherapy Treatment of Vitiligo. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer precision treatment and achieve clinical efficacy with narrowband UVB phototherapy in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress and satisfaction. The Clarify smartphone app syncs to a patented, lightweight, handheld device which guides patients through delivering targeted narrowband UVB phototherapy treatments for their specific skin conditions. All treatment records, including photographs and patient—coaching them on the use of the system and encouraging treatment adherence—greatly reducing the burden of these functions on the physician’s practice. “I am excited to join Clarify Medical at this important time in the company’s development,” said Kotcher. “The Clarify System is poised to enable many patients to safely and effectively treat their chronic skin conditions at home, and to drive substantial cost savings by enabling payers and providers to utilize this cost-effective therapy as recommended by the recently published Joint American Academy of Dermatology - National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.” Related Breaking News GlobeNewswire 05.22.20 U.S. Food and Drug Administration 05.22.20 PR Newswire 05.22.20 Business Wire 05.22.20 Roche 05.22.20 Abbott Laboratories 05.22.20 EKF Diagnostics 05.22.20 Purdue University 05.22.20 Business Wire 05.21.20 Globe Newswire 05.21.20 Business Wire 05.21.20 EKF Diagnostics 05.21.20 PR Newswire 05.20.20 Business Wire 05.20.20 Business Wire 05.20.20
CardioDx Frequently Asked Questions (FAQ)
When was CardioDx founded?
CardioDx was founded in 2003.
Where is CardioDx's headquarters?
CardioDx's headquarters is located at 600 Saginaw Dr, Redwood City.
What is CardioDx's latest funding round?
CardioDx's latest funding round is Dead.
How much did CardioDx raise?
CardioDx raised a total of $277M.
Who are the investors of CardioDx?
Investors of CardioDx include Silicon Valley Bank, Solar Capital, Asset Management Ventures, Artiman Ventures, Longitude Capital and 18 more.
Who are CardioDx's competitors?
Competitors of CardioDx include Cardiac Science Corporation, Invisible Sentinel, Integrated Diagnostics, GeneproDX, VidiStar and 12 more.
Compare CardioDx to Competitors
Adlyfe was established to develop technologies for testing for early targets of amyloid diseases. Adlyfe is developing a test for the detection of amyloid proteins as early biomarkers of fatal brain diseases. The company's technology is based on the synthesis of small peptide ligands (Pronucleon ligands) which are amino acid sequence matched to target amyloids of interest. Ligand sequences are selected based on regions of the target protein known to undergo conformational changes associated with amyloid formation. Ligand sequence selection is the basis for diagnostic specificity. The interaction of the target amyloid protein with its ligands induces the ligands to undergo a conformational change that transduces a fluorescent signal or form an association with the target that can be detected. Further amplification of the signal is generated as additional ligands are nucleated to undergo conformational changes. This is the basis for sensitivity and ability to detect very low amyloid protein levels before symptoms occur.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Atonomics develops a point of care diagnostic device based on an electro-mechanical concept. This technology changes the way that DNA and antibodies are used in point of care diagnosis.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.
Mediracer Specialises In Medical Technology. The company's Core Business Is The Development, Manufacture And Global Sale Of Point Of Care (poc) Diagnostic Testing Equipment For Diseases Of The Peripheral Nervous System.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.